Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Left ventricular hypertrophy--the problem and possible solutions.

P Gosse1

  • 1Cardiology Service-Arterial Hypertension, Hospital Saint-André, Bordeaux, France. philippe.gosse@chu-bordeaux.fr

The Journal of International Medical Research
|October 15, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Chronic pheochromocytoma-induced myocardial injuries: What should we expect from modern and classical echocardiographic tools?]

Annales de cardiologie et d'angeiologie·2020
Same author

[Alteration of left ventricular longitudinal systolic function in 2D-strain in primary aldosteronism: A new target organ damage marker].

Annales de cardiologie et d'angeiologie·2018
Same author

Sleep disruptions increase arterial stiffness.

International journal of cardiology·2015
Same author

From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency.

Journal of human hypertension·2015
Same author

Malignant hypertension and interferon-beta: a case report.

Journal of human hypertension·2013
Same author

[After STAR and ASTRAL, let's go back on earth!].

Journal de radiologie·2011
Same journal

Clinical management and genetic variation analysis of patients with 17β-hydroxysteroid dehydrogenase deficiency.

The Journal of international medical research·2026
Same journal

Totally implantable venous access port implantation in a breast cancer patient with situs inversus totalis: A case report.

The Journal of international medical research·2026
Same journal

An adaptive attention U-network for recognizing ultrasound images.

The Journal of international medical research·2026
Same journal

Examining the state of telehealth for mental health and substance use care after the coronavirus disease 2019 pandemic: An integrative review.

The Journal of international medical research·2026
Same journal

Effects of adrenal ablation on blood pressure and target organ damage in deoxycorticosterone acetate-salt hypertensive rats.

The Journal of international medical research·2026
Same journal

Regional citrate versus systemic heparin anticoagulation in continuous renal replacement therapy for sepsis-associated acute kidney injury: A retrospective cohort study of short-term outcomes.

The Journal of international medical research·2026
See all related articles

Left ventricular hypertrophy (LVH) is a reversible predictor of cardiovascular risk, linked to blood pressure. Targeting the renin angiotensin-aldosterone system (RAAS) may effectively reduce LVH and cardiovascular events.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Cardiovascular Disease

Background:

  • Left ventricular hypertrophy (LVH) signifies pathological cardiac structural changes.
  • LVH is a potent, reversible predictor of cardiovascular risk, with a continuous relationship between left ventricular mass (LVM) and cardiovascular events.
  • A strong correlation exists between LVH and blood pressure, though the mechanism by which increased cardiac workload promotes cardiovascular disease requires further elucidation.

Purpose of the Study:

  • To explore the relationship between blood pressure variability and LVH.
  • To investigate the role of the renin angiotensin-aldosterone system (RAAS) in LVH and target-organ damage.
  • To evaluate the potential benefits of RAAS-targeting agents, particularly angiotensin II receptor blockers (ARBs), in managing LVH and cardiovascular risk.

Related Experiment Videos

Main Methods:

  • Analysis of the correlation between ambulatory and resting blood pressure measurements with LVH.
  • Examination of the association between blood pressure variation, specifically the early morning rise, and increased LVM.
  • Review of the pathological role of angiotensin II and the efficacy of RAAS-inhibiting agents in LVH regression.

Main Results:

  • Ambulatory blood pressure measurements correlate more strongly with LVH than resting blood pressure.
  • An early morning rise in blood pressure is significantly associated with increased LVM.
  • Antihypertensive agents, particularly those targeting the RAAS, can induce LVH regression.

Conclusions:

  • LVH is a critical, modifiable risk factor for cardiovascular events.
  • Agents targeting the RAAS, such as ARBs, offer a promising therapeutic strategy for LVH management due to their tolerability and potential for complete RAAS blockade.
  • Pharmacological differences among ARBs may influence their cardioprotective effects beyond blood pressure reduction.